Short Interest in Asterias Biotherapeutics Inc (AST) Decreases By 5.4%
Asterias Biotherapeutics Inc (NYSE:AST) was the recipient of a significant decrease in short interest in September. As of September 29th, there was short interest totalling 2,577,169 shares, a decrease of 5.4% from the September 15th total of 2,722,903 shares. Approximately 9.4% of the company’s stock are sold short. Based on an average daily trading volume, of 84,036 shares, the short-interest ratio is currently 30.7 days.
Several hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System boosted its holdings in shares of Asterias Biotherapeutics by 4.6% in the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,100 shares during the period. Family Management Corp boosted its holdings in shares of Asterias Biotherapeutics by 15.6% in the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 6,416 shares during the period. Teachers Advisors LLC boosted its holdings in shares of Asterias Biotherapeutics by 13.1% in the second quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 6,714 shares during the period. Finally, State Street Corp boosted its holdings in shares of Asterias Biotherapeutics by 24.1% in the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock valued at $1,169,000 after acquiring an additional 63,773 shares during the period.
AST has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Monday, July 17th. HC Wainwright set a $12.00 target price on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 11th.
Asterias Biotherapeutics (NYSE:AST) opened at 3.25 on Wednesday. The company’s market cap is $162.43 million. The stock has a 50 day moving average of $3.34 and a 200 day moving average of $3.34. Asterias Biotherapeutics has a 52 week low of $2.83 and a 52 week high of $5.80.
Asterias Biotherapeutics (NYSE:AST) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The business had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.25 million. Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. On average, analysts expect that Asterias Biotherapeutics will post ($0.61) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Short Interest in Asterias Biotherapeutics Inc (AST) Decreases By 5.4%” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/11/short-interest-in-asterias-biotherapeutics-inc-ast-decreases-by-5-4.html.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.